ClinicalTrials.gg
RecruitingNCT06783829Updated Feb 27, 2025

A Study of SHR-4394 Injection in Subjects With Prostate Cancer

A Phase 1 interventional study of SHR4394 in Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
6th of 31
240 · median 69
Started
2025
with 5 others
Phase 1
14 of 31
6 open now
Primary completion
2027-03
later than 11 of 16 live
Registered
22nd of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by planned enrollment, is one of 6 that started in 2025, is one of 14 in phase 1, reaches primary completion later than 11 of the 16 other live ones, and was the 22nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 85 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: 18-85 years old, male;
  2. score for physical condition is 0-1 points;
  3. Expected survival period ≥ 6 months;
  4. Prostate adenocarcinoma confirmed by histological or cytological examination;
  5. Patients with at least one lesion;
  6. Disease progression on or after the most-recent prior regimen;
  7. Continuous treatment with luteinizing hormone releasing hormone analogues (LHRHa) or previous bilateral orchidectomy;
  8. Testosterone was at castration level;
  9. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Received systemic anticancer treatments or clinical drugs 4 weeks prior to the initiation of the study treatment;
  2. Unresolved to 5.0>=grade 2 toxicities from previous anticancer therapy;
  3. Meningeal history or clinical symptoms of central nervous system metastasis;
  4. Uncontrollable tumor-related pain;
  5. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms;
  6. Other serious concomitant disease;
  7. Previous or co-existing ;
  8. History of severe reactions to either the drug substances or inactive ingredients of SHR-4394;
  9. Active or active ;
  10. Other inappropriate situation considered by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    SHR4394

    Drug: SHR4394

Interventions

  • DrugSHR4394

    SHR4394

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: 3 weeks.

  2. Maximal tolerable dose (MTD)

    Time frame: 3 weeks.

  3. Adverse events (AEs)

    Time frame: Screening up to study completion, an average of 1 year.

  4. Recommended phase II dose (RP2D)

    Time frame: Screening up to study completion, an average of 1 year.

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: Up to approximately 2 years.

  2. Duration of response (DOR)

    Time frame: Up to approximately 2 years.

  3. Disease control rate (DCR)

    Time frame: Up to approximately 2 years.

  4. overall survival (OS)

    Time frame: Up to approximately 2 years.

07

Study locations

1 of 1 sites recruiting
  • West China Hospital of Sichuan University
    ChengDu, Sichuan 610041, China
    Recruiting
    • Qiang Wei · Contactwq933@hotmail.com · 18980601425
    • Qiang Wei · Principal investigator
    • Qiang Dong · Principal investigator
    • Ping Feng · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 26 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Jan 22, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06783829
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jan 22, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 27, 2025

Study contacts

Qi Shi
Contact
qi.Shi.qs16@hengrui.com
0518-82342973
Yueling Wang
Contact
yueling.wang@hengrui.com
021-60453139

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion